Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 5Phase 1 4Phase 3 2

Status

Completed 5Terminated 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Other solid neoplasm 1Dermatologic 1

Conditions

Colorectal Neoplasms 2Solid Tumors Harboring a BRAF V600 Mutation 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Advanced BRAF Mutant Cancers 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × encorafenib × Clear all
NCT05039177 2026-03-25

HERKULES-3

Erasca, Inc.

Phase 1/2 Completed
101 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03843775 2024-10-21

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
17 enrolled 9 charts

Advanced BRAF Mutant Cancers

NCT01543698 2024-03-13

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Pfizer

Phase 1/2 Completed
189 enrolled 44 charts
Other solid neoplasm

Solid Tumors Harboring a BRAF V600 Mutation

NCT02902042 2021-02-16

IMMU-TARGET

University Hospital, Essen

Phase 1/2 Completed
16 enrolled
Dermatologic

Melanoma

NCT02278133 2017-10-09

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Array BioPharma

Phase 1/2 Completed
20 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡